CMS ESRD Measures Manual for the 2021 Performance Period

Total Page:16

File Type:pdf, Size:1020Kb

CMS ESRD Measures Manual for the 2021 Performance Period Centers for Medicare & Medicaid Services Center for Clinical Standards and Quality CMS ESRD Measures Manual for the 2021 Performance Period Final Version 6.1 November 30, 2020 Final Centers for Medicare & Medicaid Services Table of Contents 1. Introduction .................................................................................................................. 1 2. Measurement Information .......................................................................................... 2 2.1 Vascular Access Type Clinical Measure: Hemodialysis Vascular Access: Long-term Catheter Rate (ESRD QIP and DFC) ................................................................................2 2.1.1 Measure Name .....................................................................................................2 2.1.2 Measure Description ............................................................................................2 2.1.3 Measure Rationale ...............................................................................................2 2.1.4 Measure Type ......................................................................................................2 2.1.5 Improvement Noted as Higher or Lower Rate ....................................................2 2.1.6 Numerator Statement ...........................................................................................2 2.1.7 Facility Exclusions ..............................................................................................3 2.1.8 Denominator Statement .......................................................................................3 2.1.9 Denominator Exclusions .....................................................................................3 2.1.10 Denominator Details ............................................................................................3 2.1.11 Mapping Patients to Facilities .............................................................................4 2.1.12 Calculating Numerators .......................................................................................4 2.1.13 Data Elements and Data Source ..........................................................................5 2.1.14 Flowchart .............................................................................................................6 2.1.15 Selected References .............................................................................................8 2.2 Hemodialysis Vascular Access: Standardized Fistula Rate (ESRD QIP and DFC) .........9 2.2.1 Measure Name .....................................................................................................9 2.2.2 Measure Description ............................................................................................9 2.2.3 Measure Rationale ...............................................................................................9 2.2.4 Measure Type ......................................................................................................9 2.2.5 Improvement Noted as Higher or Lower Rate ....................................................9 2.2.6 Risk Adjustment ................................................................................................10 2.2.7 Numerator Statement .........................................................................................10 2.2.8 Facility Exclusions ............................................................................................10 2.2.9 Denominator Statement .....................................................................................10 2.2.10 Denominator Exclusions ...................................................................................10 2.2.11 Denominator Details ..........................................................................................10 2.2.12 Mapping Patients to Facilities ...........................................................................11 2.2.13 Calculating Numerators .....................................................................................11 2.2.14 Statistical Risk Model and Variables ................................................................12 2.2.15 Data Elements and Data Sources .......................................................................13 2.2.16 Flowchart ...........................................................................................................16 2.2.17 Selected References ...........................................................................................17 2.3 Adult Hemodialysis Adequacy Measure (DFC Only) ....................................................18 2.3.1 Measure Name ...................................................................................................18 2.3.2 Measure Description ..........................................................................................18 2.3.3 Measure Rationale .............................................................................................18 2.3.4 Measure Type ....................................................................................................18 CMS ESRD Measures Manual for the 2021 Performance Period i Version 6.1 November 30, 2020 Final Centers for Medicare & Medicaid Services 2.3.5 Improvement Noted as Higher or Lower Rate ..................................................18 2.3.6 Risk Adjustment ................................................................................................18 2.3.7 Numerator Statement .........................................................................................18 2.3.8 Facility Exclusions ............................................................................................18 2.3.9 Denominator Statement .....................................................................................19 2.3.10 Denominator Exclusions ...................................................................................19 2.3.11 Mapping Patients to Facilities ...........................................................................19 2.3.12 Calculating Numerators .....................................................................................19 2.3.13 Assigning Patient-Months to Numerators and Denominators ...........................20 2.3.14 Data Elements and Data Sources .......................................................................20 2.3.15 Selected References ...........................................................................................21 2.4 Adult Peritoneal Dialysis Adequacy Measure (DFC Only) ............................................22 2.4.1 Measure Name ...................................................................................................22 2.4.2 Measure Description ..........................................................................................22 2.4.3 Measure Rationale .............................................................................................22 2.4.4 Measure Type ....................................................................................................22 2.4.5 Improvement Noted as Higher or Lower Rate ..................................................22 2.4.6 Risk Adjustment ................................................................................................22 2.4.7 Numerator Statement .........................................................................................22 2.4.8 Facility Exclusions ............................................................................................22 2.4.9 Denominator Statement .....................................................................................22 2.4.10 Denominator Exclusions ...................................................................................23 2.4.11 Mapping Patients to Facilities ...........................................................................23 2.4.12 Calculating Numerators .....................................................................................23 2.4.13 Assigning Patient-Months to Numerators and Denominators ...........................23 2.4.14 Data Elements and Data Sources .......................................................................23 2.4.15 Selected References ...........................................................................................24 2.5 Pediatric Hemodialysis Adequacy Measure (DFC Only) ...............................................25 2.5.1 Measure Name ...................................................................................................25 2.5.2 Measure Description ..........................................................................................25 2.5.3 Measure Rationale .............................................................................................25 2.5.4 Measure Type ....................................................................................................25 2.5.5 Improvement Noted as Higher or Lower Rate ..................................................25 2.5.6 Risk Adjustment ................................................................................................25 2.5.7 Numerator Statement .........................................................................................25 2.5.8 Facility Exclusions ............................................................................................25 2.5.9 Denominator Statement .....................................................................................25 2.5.10 Denominator Exclusions ...................................................................................26
Recommended publications
  • KIDNEY FAILURE TREATMENT OPTIONS Choosing What’S Best for You What Kidneys Do
    KIDNEY FAILURE TREATMENT OPTIONS Choosing What’s Best For You What Kidneys Do The kidneys are a pair of bean shaped organs located below your ribcage near the middle of your back. Kidneys play a vital role in the body by filtering blood, removing waste and extra water, balancing electrolytes—sodium, potassium, chloride, and biacarbonate, and regulating blood pressure. As kidneys filter blood they create urine/wastes which collect in the bladder until you go to the bath- room. If your body doesn’t remove these wastes, they build up in the blood and damage the body. For most people this damage occurs slowly over many years causing Chronic Kidney Disease (CKD). CKD eventually results in End Stage Renal Disease (ESRD) which is when dialysis or a transplant becomes necessary. 2 TREATMENT OPTIONS Treatment Options This guide will cover four treatment options for your condition: l Hemodialysis (in-center & home) l Peritoneal Dialysis l Kidney Transplantation l Comfort Care Introduction When diagnosed with kidney disease, the key to feeling better is to follow the treatment plan developed by your doctor and other members of your care team including nurses, dietitians, and social workers. Following the advice of your medical professionals will help you lead the healthiest lifestyle possible. When your kidneys are unable to remove extra fluid and waste from the body, dialysis is generally recommended. Dialysis helps alleviate many of the health problems people with kidney failure experience. Dialysis can be done in a hospital, a dialysis clinic, or at home. Once you know all of your treatment options, you will make the decision of where you choose to have dialysis with the help of your doctor, other health care professionals, and your family.
    [Show full text]
  • Dialysis Dosing: Kinetics Versus Physiology
    Dialysis Dosing: Kinetics Versus Physiology KDIGOMaría F. Slon Complejo Hospitalario Navarra Navarra, Spain Disclosure of Interests • NxStage European Medical Advisory Board KDIGO KDIGO Controversies Conference on Dialysis Initiation, Modality Choice & Prescription January 25-28, 2018 | Madrid, Spain Epidemiology Estimated number of patients undergoing RRT from 2010 to 2030 worldwide (A) and by region (B) KDIGO Liyanage T, et al. Lancet 2015 Epidemiology Expected remaining lifetime (years) of the general population (cohort 2011-2015) and of prevalent dialysis and transplant patients (cohort 2011-2015) KDIGO ERA-EDTA Registry Annual Report 2015 Epidemiology Unadjusted percentages of deaths in 2014 by cause, excludes missing/unknown causes of death data among dialysis patients Cardiovascular disease > 50% KDIGO Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident. USRDS Annual Data Report 2017 Dialysis Therapy SOLUTES CLEARANCE Uremic Toxins HORMONE PRODUCTION Electrolites Regulation Red blood cell mass Acid–base Balance regulation Calcium–phosphate Vitamin D regulation control KDIGO Others VOLUME HOMEOSTASIS Fluid Overload Blood pressure control Dialysis Therapy SOLUTES CLEARANCE Convetional Uremic Toxins Hemodialysis Electrolites Regulation Acid–base Balance Peritoneal dialysis Calcium–phosphate control KDIGO Hemodiafiltration technologies VOLUME HOMEOSTASIS Intensive Hemodialysis Fluid Overload Blood pressure control Ability for solute clearance,
    [Show full text]
  • Home Dialysis
    Have you thought about DIALYSIS at There is more than one HOME? way to treat kidney failure. Choosing your treatment is about helping you live your life. GETTING INVOLVED REALLY MATTERS You’ll feel more in charge if you take an active role in the decision. Your kidney team should tell you about all treatment options and the pros and What are the first steps? cons of each. But you make Learn about the different options for treatment of kidney failure. the choice based on your n Talk to the professionals who are treating you. needs, lifestyle, medical n Ask questions: conditions, and current • What treatments are done at home? level of kidney function. In • Am I eligible for home treatments? • How will my choice of treatment affect my order to make this decision, health and lifestyle? you need to learn about all • At this point in my kidney disease, is one choice better than another? the treatments. • Will one treatment better protect my remaining kidney function? Which one? 2 Where can you learn about your options? When you have kidney disease, a team of professionals (your kidney team) will help you understand how your choice will affect your life. Ask questions to be sure what the right option is for you. Discuss the things that are most important to you and any concerns or worries you may have. Visit the National Kidney Foundation website at www.kidney.org for helpful resources. You can also call the NKF Cares patient help line toll-free at 1.855.NKF.CARES (1.855.653.2273) or email [email protected].
    [Show full text]
  • Perspectives of Dialysis Patients
    Department of Health and Human Services OFFICE OF INSPECTOR GENERAL “KNOW YOUR N(JMBER” BROCHURE PERSPECTIVES OF DIALYSIS PATIENTS JUNE GIBBS BROWN Inspector General JANUARY 1997 OEI-06-95-O0320 OFFICE OF INSPECTOR GENERAL The mission of the OffIce of Inspector General (OIG), as mandated by Public Law 95-452, is to protect the integrity of the Department of Health and Human Services programs as well as the health and welfare of beneficiaries served by them. This statutory mission is carried out through a nationwide program of audits, investigations, evaluations, sanctions, and fraud alerts. The Inspector General informs the Secretary of program and management problems and recommends legislative, regulatory, and operational approaches to correct them. OFFICE OF EVALUATION AND INSPECTIONS The OIG’S OffIce of Evaluation and Inspections (OEI) conducts short-term management and program evaluations (called inspections) that focus on issues of concern to the Department, the Congress, and the public. The inspection reports provide findings and recommendations on the efficiency, vulnerability, and effectiveness of departmental programs. OEI’S Dallas Regional Oftlce prepared this report under the direction of Chester B. Slaughter, Regional Inspector General. Project staff included: DALLAS REGION HEADQUARTERS Michelle Adams, Ph. D. Mary Beth Clarke Ruth Ann Dorrill Brian Ritchie Karen Erickson, Intern Barbara Tedesco Sarah Taylor Judy Tyler Nancy Watts For additional copies of this report, please contact the Dallas Regional OffIce at (800) 848-8960. Department of Health and Human Services OFFICE OF INSPECTOR GENERAL “KNOW YOUR NUMBER” BROCHURE PERSPECTIVES OF DIALYSIS PATIENTS $‘o + JUNE GIBBS BROWN Inspector General ‘+4b dza # J~ARY 1997 OEI-06-95-O0320 EXECUTIVE SUMMARY PURPOSE This study describes the perspectives of end stage renal disease (ESRD) patients regarding the effectiveness of the Health Care Financing Administration’s (HCFA) “Know Your Number” brochure in educating them about a way to monitor the adequacy of their dialysis.
    [Show full text]
  • Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate
    الجامعةةةةةةةةةةةةةةةةةةةةة اﻹسةةةةةةةةةةةةةةةةةةةة مية بغةةةةةةةةةةةةةةةةةةةة زة The Islamic University of Gaza عمةةةةةةاحة البحةةةةةةد العلمةةةةةةي والد اسةةةةةةا العليةةةةةةةا Deanship of Research and Graduate Studies كليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة العلةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةو Faculty of Science Master of Biological Sciences ماجسةةةةةةةةةةةةةةةةةةتير العلةةةةةةةةةةةةةةةةةةو الحياتيةةةةةةةةةةةةةةةةةةةة Medical Technology التحةةاليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةل الطبيةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى مرضى الفشل الكلوي المزمن في مستشفى الشفاء - محافظة غزة Prepared By Fawwaz H. Eliglah Supervisor Prof. Baker M. Zabut Faculty of Science Biochemistry Department The Islamic University of Gaza A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biological Sciences- Medical Technology September , 2018 إقةةةةةةةةةةةةةةرا أنا الموقع أحناه مقد الرسالة التي تحمل العنوان: Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى ي مرضى الفشل الكلو المزمن في مستشفى الشفاء - محافظة غزة أقر بأن ما اشتملت عليه هذه الرسالة إنما هو نتاج جهدي الخاص، باستثناء ما تمت اﻹشارة إليه حيثما ورد، وأن هذه الرسالة ككل أو أي جزء منها لم يقدم من قبل اﻻخرين لنيل درجة أو لقب علمي أو بحثي لدى أي مؤسسة تعليمية أو بحثية أخرى. Declaration I understand the nature of plagiarism, and I am aware of the University’s policy on this. The work provided in this thesis, unless otherwise referenced, is the researcher's own work, and has not been submitted by others elsewhere for any other degree or qualification. اسم الطالب: فواز حسن العجلة :Student's name التوقيع: Signature: Fawwaz H.
    [Show full text]
  • Choosing the Right Treatment Method – Exploring Home Dialysis Options
    Choosing the Right Treatment Method – Exploring Home Dialysis Options Presented by: Mikie Cooke, MSW, ACSW and Erick Smith Thanks to our speakers! Mikie Cooke, MSW, ACSW PATHfinder™ Satellite Healthcare Erick Smith PATHfinder™ Satellite Healthcare Learning Outcomes After this webinar attendees should understand: • The importance of goal setting when choosing a dialysis treatment option. • Hemodialysis, including home hemodialysis and why someone should choose this option. • Peritoneal dialysis and why someone should choose this option. Audience Poll What is your connection to kidney disease? 1. I have kidney disease 2. I am a family member or caregiver for someone with kidney disease 3. I work with patients with kidney disease If you work for a dialysis company, which company do you work for? 1. Fresenius 2. DaVita 3. Satellite 4. Other If you are a dialysis patient, which treatment method do you currently use? 1. In-center hemodialysis 2. Home hemodialysis 3. Peritoneal dialysis If you are a health care professional, which dialysis treatment method would you choose? 1. In-center hemodialysis 2. Home hemodialysis 3. Peritoneal dialysis The Importance of Goal Setting • What inspires you? • Inspiration leads to motivation • Motivation leads to change in behavior https://www.sandler.com/blog/motivation-and-discipline-how-managers-can-use- both-lead-successful-team Education • What type of water source would you like to drink out of? Steps to Starting • Education • Decision • Surgery • Healing • Training • Maintenance Why are we talking about this? Distribution of renal replacement therapy modality used by ESRD patients, by country, 2015 USA Qatar Denmark Australia Canada Colombia Thailand New Zealand Hong Kong 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Peritoneal Dialysis Home Hemodialysis Transplant In-Center Hemodialysis Data from 2017 USRDS Annual Report; accessed on Nov.
    [Show full text]
  • Writing the Home Hemodialysis (HHD) Prescription
    ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM This image cannot currently be displayed. Writing the Home Hemodialysis (HHD) Prescription Joel D. Glickman, MD • Professor of Clinical Medicine • Perelman School of Medicine • University of Pennsylvania 2 This image cannot currently be displayed. Goals For A Successful HHD Prescription • SOLUTE REMOVAL • Small solute target: std Kt/V > 2.0 • Achieved with lower spKt/V than in-center HD • For 5 treatment per week target spKt/V ~ 0.55 - 0.60 • For 6 treatment per week target spKt/V ~ 0.45 • Phosphate clearance • Middle Molecule clearance • FLUID REMOVAL • Avoid high ultrafiltration rates • QUALITY OF LIFE • Need to match prescription to patient lifestyle 3 This image cannot currently be displayed. Typical Treatment Parameters For HHD NxStage Traditional Equipment “Low dialysate volume approach” Conventional SDHD* NHD** SDHD NHD HD Treatments/Wk 3 5-6 5-6 5-6 5-6 Treatment 4 2 6-8 2.25-3 6-8 Time (Hrs) Qb (ml/Min) 400 400 200-250 400 200-250 Qd (ml/Min) 600-800 600-800 300 130-200 60-80 * SDHD = short daily hemodialysis ** NHD = nocturnal hemodialysis 4 This image cannot currently be displayed. SDHD - Traditional technology . 5 Approach is exactly the same as in-center HD • Clearance • Qb 400; Qd 600 • Typical spKt/V ~ 0.8 • Time on therapy • 2 hours – adjust to achieve target clearance • Potassium • Adjust according to blood test results • Bicarbonate • Adjust according to blood test results • Calcium • Adjust according to blood test results • Heparin • Bolus 1500-3000 units This image cannot currently be displayed. New Technology Technology should adapt to patient’s needs.
    [Show full text]
  • Increasing Blood Flow Rate; a Tool to Improve Adequacy of Dialysis
    ORIGINAL ARTICLE ISRA MEDICAL JOURNAL | Volume 9 - Issue 6 | Nov - Dec 2017 Increasing Blood Flow Rate; A Tool To Improve Adequacy Of Dialysis Aurangzeb Afzal1, Maira Iqbal Malik2, Adnan Shabbir2 ABSTRACT OBJECTIVE: To assess the effect of increasing blood flow rate on the adequacy of dialysis, and to prove that increased blood flow can be helpful in achieving adequate dose of dialysis, in patients having low efficiency of dialysis . STUDY DESIGN: Quasi experimental study PLACE AND DURATION: At Dialysis unit of Lahore General Hospital over a period of 1 month from 28th January to 28th February 2017. METHODOLOGY: A total of 40 patients on regular hemodialysis participated in this study. Hemodialysis was performed at two different blood flow speeds 300 and 350 ml/min. Blood samples were obtained just before start and 45 minutes after completion of dialysis to measure urea levels. Urea Reduction Ratio (URR) was used as an index of dialysis dose and hence dialysis efficiency. RESULT: Increasing blood flow rate from 300 to 350ml/min has a significant impact on URR and hence on dialysis adequacy. It was observed that increasing blood flow rate from 300ml/min to 350ml/min raised URR from 53% to 60%. Marked statistical difference in URR between the two groups that is 7% was observed using the paired T-test. P value was 0.001 (<0.05). CONCLUSION: Increasing blood flow rate (BFR) has been successful in boosting effective dose of dialysis and is likely to prove beneficial for patients requiring hemodialysis. KEYWORDS: Hemodialysis, Adequacy, Blood Flow Rates, Low Efficiency, Urea reduction ratio.
    [Show full text]
  • Renal Replacement Therapy: Options and Choices
    Renal Replacement Therapy: Options and Choices Marc L. Weber, M.D. Nephrologist University of Minnesota Minneapolis, MN That disclosure slide… • I have no financial or other disclosures and will not discuss off label use of any medication. Learning Objectives • Identity renal replacement therapy options for patients with end stage renal disease (ESRD). Self Assessment Questions • 1. Renal replacement therapy should be considered if the patient is experiencing: o A. Hyperkalemia o B. Metabolic acidosis o C. Fluid overload o D. All of the above • 2. Types of Hemodialysis access include: o A. Fistula o B. Graft o C. Catheter o D. All of the above Indications for Renal Replacement Therapy • Hyperkalemia* • Metabolic acidosis* • Fluid overload (recurrent CHF admissions)* • Uremic pericarditis (rub) • Other non specific uremic symptoms: anorexia and nausea, impaired nutritional status, increased sleepiness, and decreased energy level, attentiveness, and cognitive tasking, … *Refractory to medical management Treatment Options for Kidney Failure ESRD Comfort Care Hemodialysis Peritoneal Dialysis Kidney Transplant ESRD, end-stage renal disease Treatment Options for Kidney Failure ESRD Comfort Care Hemodialysis Peritoneal Dialysis Kidney Transplant Dialysis Options Dialysis In-Center(dialysis clinic) Home In-Center Hemodialysis Peritoneal Dialysis -3 x week -Manual (CAPD) -Nocturnal -Cycler (CCPD) Home Hemodialysis -3-5 x/week -Day or nocturnal What is the most common modality to replace kidney function? A. In-Center(clinic) Hemodialysis B. Peritoneal
    [Show full text]
  • Home Hemodialysis with Nxstage
    Welcome to our August Webinar on Home Dialysis: Is It Your Best Treatment Option? We need your Feedback - Please complete after the program! This webinar will be recorded and slides will be available at www.dpcedcenter.org Next webinar on 9-27-18 with Edward Leigh on Communicating with your Healthcare Team: Top Tips to Prepare for Visits and Partner with Professionals! Reminder ➢ All phone lines are muted ➢ You can ask questions through the Chat Box ➢ Or, at the end of the presentation, you can ask questions by unmuting your phone (Unmute: #6, then Mute *6 ) ➢ Webinar Recording and slides will be available on our web site ➢ Please complete the feedback form at the end of the program ➢ Please share the information with others Join us next month on 9-27-18 for our webinar: Communicating with your Healthcare Team: Top Tips to Prepare for Visits and Partner with Professionals! Today’s Speakers Dr. Michael Kraus, MD, FACP Vanessa Evans Nephrologist, Patient Advocate Manager, Indiana University School of Medicine NxStage Medical, Inc. Associate Chief Medical Officer, Dialysis patient for 20 years, the last 13 years NxStage Medical, Inc. on more frequent home hemodialysis with NxStage. Page 3 Home Hemodialysis: Is it your best treatment option? Page 4 Agenda ▪ What are my treatment options? ▪ Why would I want to dialyze more than 3 days a week? ▪ Why would I want to go home? ▪ Vanessa’s Dialysis Story ▪ Questions and Answers What is your current dialysis therapy? What Are My Treatment Options? Page 7 Treatment Options: What do they mean? In-Center Hemodialysis Peritoneal Dialysis Home Hemodialysis Kidney Transplantation The traditional approach.
    [Show full text]
  • Read Comments on ESRD PPS QIP And
    30 E. 33rd Street New York, NY 10016 Tel 212.889.2210 Fax 212.689.9261 www.kidney.org September 4, 2018 Seema Verma Administrator Centers for Medicare and Medicaid Services Room 314G Hubert H. Humphrey Building, 200 Independence Avenue, SW Washington, DC 20201 RE: CMS-1691-P: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments to Correct Existing Regulations Related to the CBP for Certain DMEPOS Dear Administrator Verma: The National Kidney Foundation appreciates the opportunity to comment on the proposed changes to the end-stage renal disease (ESRD) prospective payment system (PPS), including policies that will govern coverage and payment for renal dialysis services delivered to individuals with acute kidney injury (AKI), and the quality incentive program (QIP) for payment years 2021- 2024. The National Kidney Foundation is the largest, most comprehensive and longstanding, patient centric organization dedicated to the awareness, prevention and treatment of kidney disease in the US. In addition, the National Kidney Foundation has provided evidence-based clinical practice guidelines for all stages of chronic kidney disease (CKD), including transplantation since 1997 through the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI). This year we are dividing our comments into three separate letters in hopes to make it easier to review our recommendation on each section of the rule. This letter responds to the solicitation for information on transplantation and home dialysis.
    [Show full text]
  • Management of Hypertension for Patients Undergoing Dialysis Therapy Yoshihiro Taniyama
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Taniyama Renal Replacement Therapy (2016) 2:21 DOI 10.1186/s41100-016-0034-2 REVIEW Open Access Management of hypertension for patients undergoing dialysis therapy Yoshihiro Taniyama Abstract Hypertension is very prevalent among patients undergoing dialysis therapy: hemodialysis (HD) and peritoneal dialysis (PD). Although it is recognized as a great risk of cardiovascular mortality for these populations, how to regulate blood pressure (BP) is poorly understood. For HD patients, we should pay much attention to methods of measuring BP. Out- of-center BP levels and BP variability should be evaluated by ambulatory BP monitoring and home BP measurement because they are closely associated with cardiovascular mortality. Although target BP levels are not clear, several clinical guidelines suggest <140/90 mmHg. However, it must be determined for each individual patient with careful considerations about comorbidities. Based on the underling pathophysiology of hypertension in patients on dialysis, maintaining an appropriate volume of body fluid by dietary salt restriction and optimization of dry weigh should be considered as a first line therapy. Inhibitors for renin-angiotensin system may be suitable to reduce BP and mortality for those patients on dialysis. These drugs may also be effective for preserving residual renal function and peritoneal function for PD patients. β-blockers may have potentials to improve survival for HD patients and can be added to anti- hypertensive medications. Lacking large-scale and good quality clinical trials, there are many questions to be answered. Much effort should continuously be made to create evidences for better management of hypertension for patients on dialysis therapy.
    [Show full text]